In
the past few years, I have become progressively more aware of the
foundational importance of optimal mitochondrial function for health and
the growing body of research showing that dysfunction is surprisingly
common and associated with most chronic disease. In my IMCJ
12.5 editorial, Lara and I presented helpful clinical pearls on
mitochondrial health from the Institute of Functional Medicine
conference in Dallas last spring. In my IMCJ 13.1 editorial, I
stated that glutathione is “… vital to mitochondrial function and
maintenance of mitochondrial DNA (mtDNA).” I have found the
mitochondrial connection to health so interesting and important that I
have now developed a 90-minute lecture on the topic and think the time
has come for an editorial.
As illustrated in Table 1,
with such a long list of common diseases now caused by or aggravated by
mitochondrial dysfunction, it is difficult to overstate its importance.
Table 1
|
How Much ATP Does the Body Produce Every Day?
I
wish there were some way to cover up the answer—before you, dear
reader, answer this question (please take a moment and guess how many
g/d)—as I am sure everyone would guess wrong. Well, I should have said
“almost everyone,” as we have some exceptionally knowledgeable readers.
Having asked this question the 3 times I have given my mitochondrial
lecture, no one was within 2 orders of magnitude of the correct answer. A
healthy person at rest produces their body weight in adenosine
triphosphate every day! At maximal exercise, this number can increase to
0.5 to 1.0 kg per minute—a truly remarkable indication of intense
metabolic activity.
A large amount of adenosine
triphosphate (ATP) must be produced by the mitochondria every second of
every day because ATP cannot be stored. This function is so important
that mitochondria can take up as much as 25% of the cell volume. Cells
contain from 1000 to 2500 mitochondria.1 The average cell uses 10 billion ATP per day, which translates to the typical adult needing 3.0 × 1025
ATP (I am publishing these numbers with some trepidation as the
research is surprisingly inconsistent about exactly how much ATP a cell
needs).2
To accomplish this prodigious feat, each ATP needs to be recycled from
ADP 1000 times per day. Because the body cannot store ATP, the
mitochondria must function consistently all the time. At any given time
there are about 250 g of ATP in the cells. This represents about 4.25
watts, the equivalent of the energy in an AA battery. Every day, a
healthy person produces a remarkable 1200 watts!3
Because the brain uses 70% of ATP, this helps explain the strong
correlation between mitochondrial dysfunction and neurodegeneration.
The
production of ATP is quite a complex process, starting in the Krebs
citric acid cycle, also known as the tricarboxylic acid cycle (TCA), as
seen in Figure 1.
But far more important than direct ATP production are the high-energy
molecules the TCA provides the electron transport chain (ETC), as seen
in Figure 2. This is where 90% of ATP are produced in aerobic metabolism.
The ETC, as seen in Figure 3,
is complex and quite fascinating. All the action occurs in and across
the mitochondrial membranes and is highly dependent on the nutritional,
toxic, and redox potential of the cell and mitochondria.
Mitochondrial Function and Protection
The
mitochondria are especially susceptible to nutrient deficiencies,
environmental toxins, and oxidative damage. Although many nutrients are
necessary for ATP production, the most important are listed in Table 2.
Table 2
|
Research
now shows that the primary source of oxidative stress in cells is
leakage of oxygen and high-energy electrons from the mitochondria. This
leakage increases when key nutrients/protective molecules are missing,
such as the dose-dependent depletion of CoQ10 in patients taking statin drugs—a problem that has been known for a long time.7 Note in Figure 3 that the high-energy electrons are transported between the various mitochondrial complexes by CoQ10. Many factors are associated with increased damage to the mitochondria. The following list in Table 3 is by no means complete but is clinically relevant.
Table 3
|
Mitochondrial
reactive oxygen leakage is a strong predictor across species for
longevity—the better a species does protecting its mitochondria, the
longer a species lives. Oxygen is essential for energy production and
dangerous when not totally controlled. At rest, the body uses 1 kg of
oxygen per day. During maximal exercise this can increase to 10 to 20 g
per minute! As 1%–2% of oxygen is lost in “normal” mitochondria, this
translates to 10 to 20 g O2 lost per day at rest and 200 mg
per minute at maximal exercise. Obviously this represents huge oxidative
stress, which explains why mitochondrial ROS production and leakage are
the major source of intracellular oxidants. With age, mtDNA damage
accumulates, resulting in even more oxygen and high-energy electron
loss.8
This helps explain why people start “losing energy” once they reach
around 55 years of age. The primary ways the mitochondria are protected
from this intense oxidative stress are manganese-dependent superoxide
dismutase, catalase, CoQ10, vitamin E, and glutathione (produced in cytoplasm and transported across the mitochondrial membrane).
Many
prescription drugs damage mitochondria via a diverse range of
mechanisms too complex to cover here. Among the worse are shown in Table 4. As you can see, these are all commonly prescribed.
Table 4
Acetaminophen |
Antibiotics |
Aspirin |
AZT |
Cocaine |
Grisepfulvin |
Indomethacin |
Methamphetamine |
l-DOPA |
NSAIDs |
Statins |
These
are all of significant concern, but particularly of concern are those
prescribed frequently or taken for a long time. Some antibiotics, for
example, not only impair ATP production; they also increase ROS
production and damage mtDNA. The degree of mtDNA damage can be
indirectly measured by 8-hydroxy-2′-deoxyguanosine (8-OHdG) in the
urine. The numbers in Table 5
are cause for grave concern. This is new research from cell cultures
and animals. It is reasonable to assume humans react similarly, though
the research has yet to be published.9 Note especially the high level of mtDNA damage from ampicillin.
Table 5
After 4 Days | Ciplofloxan | Ampicillin | Kanamycin | Tetracycline |
---|---|---|---|---|
ATP production | −90% | −75% | −80% | −20% |
ROS | +250% | +200% | +240% | +40% |
MDA | +90% | +80% | +75% | +20% |
8-OHdG | +100% | +720% | +400% | +230% |
Another
serious concern is the widespread and growing use of statin drugs. Many
of the adverse events associated with these prescriptions are well
explained by the mitochondrial dysfunction they induce, secondary to
depletion of CoQ10. It is not surprising that statins increase all-cause mortality and most chronic disease.10
Recreational drugs are a problem as well. The research is too early on
marijuana, but alcohol is clear: The more consumed, the greater the
depletion of NADH needed for ATP production. In addition, ROS production
is increased.11
Assessing Mitochondrial Function
At
this time, there are no clinically available tests to directly measure
mitochondrial ATP production. However, as several procedures are now
being used in research laboratories, I think it is only a matter of time
until 1 or more become commercially available. (Two years ago, I worked
with a lab to try to make such a test available, but technical
challenges resulted in it not being cost effective and the results not
adequately reliable.)
Fortunately, there are clinical assessment and indirect laboratory tests. Figure 4
shows the probability of mitochondrial dysfunction in various signs,
symptoms, and diseases. There are several indirect measures of
mitochondrial dysfunction.12
Most readily available are blood levels of lactate and pyruvate.
However, these tests are quite susceptible to sampling error, recent
exercise, and so forth, and they will only become abnormal when the
mitochondrial dysfunction is so bad that anaerobic metabolism has to
compensate. Urinary organic acid analysis can be quite useful for
determining enzyme dysfunction in the citric acid cycle, which can
pinpoint where the problem is. Finally, the amount of damage to the
mtDNA can be estimated by 8-OHdG in the urine. Interestingly, this test
also predicts cancer risk—not the type of cancer but rather the amount
of DNA damage, which leads to cancer.13
Strategies to Improve Mitochondrial Function
- Pick the right mother. Sorry, couldn’t resist, but starting out with optimal mtDNA certainly helps.
- Optimize nutrient status to limit oxygen and high-energy electron leakage in the ETC. As the greatest source of oxidative stress and damage to mtDNA, this is perhaps the most powerful antiaging strategy we can provide our patients.
- Decrease toxin exposure. This is obviously true for virtually every disease, but because of the huge metabolic activity of the mitochondria, they are especially susceptible.
- Provide nutrients that protect the mitochondria from oxidative stress.
- Utilize nutrients that facilitate mitochondrial ATP production.
- Build muscle mass. Even those with mitochondrial damage, such as that found in Parkinson’s disease, can increase ATP production through strength training.15
Of
course, the order of these priorities can be argued, but the basic need
is clear and I recommend all of them, especially the critical natural
health products at the dosages required to accomplish the goals. The
foundation begins with a good multivitamin and mineral. They should be
high quality with 2 to 3 times the recommended daily intake for most
nutrients, especially the B vitamins. Of all the mitochondrial
supportive nutrients, at the top of my list are (in order of my
preference—which I am sure is debatable) CoQ10, α-lipoic acid plus acetyl-l-carnitine, resveratrol, NAC, and vitamin E. Also of value are coconut oil, pyrroloquinoline quinone (PQQ), Ginkgo biloba, proanthocyanidins, and melatonin.
CoQ10
There are many reasons to recommend CoQ10. As can be seen in Figure 3, CoQ10
carries the high-energy electrons through the ETC. Deficiency means not
only decreased ATP production but also increased electron loss causing
oxidative damage. CoQ10 is also an important
intramitochondrial antioxidant right where those ROS are being produced.
It is not surprising that research has shown a strong correlation
between a species’ ability to produce CoQ10 and their longevity.16 Clinical research on supplemental CoQ10 is positive and growing17 (100 mg QD).
α-Lipoic Acid + Acetyl-l-Carnitine
Resveratrol
The
good news keeps coming on resveratrol—wine lovers rejoice! (Of course,
there are several other “food” sources.) Resveratrol increases
mitochondrial ATP production, protects from ROS, up-regulates sirtuin 1,
and so forth.20 It even clears β-amyloid from Alzheimer’s disease cells.21 Human studies are now confirming animal studies showing improved mitochondrial functional at surprisingly reasonable dosages.22 (150 mg QD.)
N-Acetyl Cysteine (NAC)
As I discussed in my glutathione editorial in IMCJ
13.1, the key role of NAC is to increase intracellular glutathione,
which is then pumped into the mitochondria. This glutathione is critical
for protection of mitochondria from oxidative damage. (500 mg BID.)
Vitamin E
Not
surprising to find extensive cell and animal research showing that the
antioxidant vitamin E protects mitochondria from oxidative stress. The
human research is not as strong and unfortunately is almost all with a
single member of the vitamin E family. Nonetheless, there are promising
early results.23 (Mixed tocopherols 500 IU QD.)
Summary
There
is so much more that could be written about mitochondria from the
perspective of an integrative medicine clinician. I think we are seeing
only the tip of the iceberg of the role of mitochondrial dysfunction in
our patients’ disease and ill health. As the environment becomes more
polluted and drug prescribing increases, this problem will become even
worse. The good news is that there is a lot we can do to help.
In This Issue
As I have mentioned several times before, one of the joys as editor of IMCJ is reading the reviews of associate editor Sid McDonald Baker, md.
If it weren’t such a burden, I’d send him every submission for review.
As has been the case before, his review of a paper was so insightful, I
thought IMCJ readers would find value:
Authors writing on behalf of and for the integrative medicine community should feel obliged to avoid the fallacy of traditional medicine that diseases are entities that cause symptoms. This requires vigilance against old habits that come out when we say something like “compounding the impact of these conditions on individuals health systems and populations.” Comorbidity is another word we should all watch out for. It carries this silly notion that complex chronic illness is somehow the sum of the combined “attack” by each of several “disease entities.” Schizophrenia is a catchy word and it is tempting to use it in a title of an article about a dramatic clinical response. In the long-run, however, I think it would be safer to simply say hallucinations, night terrors, and abdominal pain to characterize the boy’s troubles.
Yes,
conventional medicine’s standardization of disease, disease diagnosis,
and disease treatment has facilitated critical advances in many areas.
Unfortunately, this perspective has also greatly impaired recognizing
the uniqueness of the patient who “has the disease” and has led to the
symptomatic treatment—at the expense of curative care. This is at the
heart of the health care crisis.
I really like our
original research in this issue as it demonstrates that acupuncture can
generate measurable physiological changes in the body. I think
particularly of interest is that the research by Jeannette Painovich, daom, lac; Anita Phancao, md; Puja Mehta, md; Supurna Chowdhury, ms; Shivani Dhawan, ms; Ning Li, phd; Doris Taylor, phd; Yi Qiao, lac; Anna Brantman, daom, lac; Xiuling Ma, phd, lac; and C. Noel Bairey Merz, md, implies that acupuncture can have a regenerative effect.
Since my first editorial in IMCJ
1.1 over a decade ago, I have preached the gospel of collaboration
providing our patients the best opportunity for optimal clinical
outcomes. Ruthann Russo, phd, jd, mph, lac,
explores the intriguing concept that with the growing public acceptance
and research foundation for nonconventional interventions, informed
consent could now legally mean that a conventional doctor must inform
their patients of these other options. I find this especially
interesting since some state licensing laws require CAM practitioners to
inform their patients of conventional interventions. “The Times, They
are a-Changin’ …”
Over 40 years ago as a naturopathic
student, I was taught by Dr Bastyr the use of the “vag pack” and
escharotics for the treatment of cervical dysplasia (there we go
again—naming the disease). Specializing in natural childbirth, I
successfully used this protocol to help a lot of women (along, of
course, with optimizing their nutrition, cleaning up their diet, etc).
So I am quite excited to see a good case study on the use of this
protocol by Kimberly Windstar, med, nd; Corina Dunlap, ba; and Heather Zwickey, phd. This kind of research is critical for advancing the foundation of this medicine. Michael Murray, nd, and I had a chapter and appendix on cervical dysplasia and the vag pack way back in the first (1985) version of the Textbook of Natural Medicine. Since then, associate editor Tori Hudson, nd, has written about and taught this procedure to many integrative medicine clinicians.
Our interview this month is with Sarah Speck, md, and Dan Tripps, phd. I had an opportunity to tour their integrative cardiac function—not disease—assessment clinic in Seattle and was so impressed I thought IMCJ
users would also be interested. Talking to them I developed a better
understanding of the clinical significance of how various types of
fitness training can imbalance a person’s anaerobic/aerobic capacity.
This was really brought home to me recently when I prescribed strength
training to an adolescent with a mitochondrial deficit. Based on my
understanding as described above, I had already optimized his
mitochondria as best I could with nutrition; now I wanted to increase
his number of mitochondria. I was surprised—and impressed—when I heard
back from the mother that the trainer wanted to know if I wanted to
build lean or bulky muscle! Very good question. My assumption is that
lean muscle would be the most aerobic, so that is what I prescribed.
Reading this interview reminded me that now I no longer need to
assume—Dr Speck and Dr Tripps can measure. So I just made the referral.
The keynote speaker we are featuring is Michael Greger, md,
who will be covering “Reversing Chronic Disease Through Diet” at the
American Association of Naturopathic Physicians Conference in August. Of
course, all IMCJ readers are quite knowledgeable in this area.
What I found most interesting is his candid comments about the intense
politics involved in setting the USDA Dietary Guidelines.
I
fully concur with John Weeks that our field owes a great debt of
gratitude to Senator Tom Harkin (D-IA) for his adamant advocacy of
integrative medicine at the federal level. The original Office of
Alternative Medicine, the CAM Caucus, the White House Commission on
Complementary and Alternative Medicine (on which I was privileged to
serve), the National Center for Complementary and Alternative Medicine
at the NIH— his remarkable leadership and accomplishments have been
pivotal in the maturation and acceptance of this medicine.
Congratulations to Patricia Herman, nd, phd, and Dugald Seely, nd,
for publication of their seminal cost-effectiveness research. This is
the kind of work we need to provide corporate decision makers the
justification to explore other—and we believe better!—ways of promoting
health in the workplace.
As usual, great BackTalk by Bill Benda, md.
His comments about the hyping and marketing of medicine that drives us
so crazy are right on. Thanks for the very kind compliment (I think), Dr
Bill—but it is “Dr Joe” now …
Joseph Pizzorno, nd, Editor in Chief
References
1. No authors listed. Mitochondrian Wikipedia. [Accessed February 11, 2014]. http://en.wikipedia.org/wiki/Mitochondrion. Updated February 17, 2014.
2. Phillip M, Milo R. BioNumber of the Month. [Accessed February 12, 2014]. http://openwetware.org/wiki/BioNumber_Of_The_Month. Updated September 18, 2009.
3. Törnroth-Horsefield S, Neutze R. Opening and closing the metabolite gate. Proc Natl Acad Sci U S A. 2008;105(50):19565–19566. [PMC free article] [PubMed]
4. Narayanese, WikiUserPedia, Yassine Mrabet, Toto Baggins, available at http://commons.wikimedia.org/wiki/File:Citric_acid_cycle_with_aconitate_2.svg.
5. Wikipedia Creative Commons, available at http://commons.wikimedia.org/wiki/File:Mitochondrial_electron_transport_chain%E2%80%94Etc4.svg#.
6. Wikipedia Creative Commons, available at http://commons.wikimedia.org/wiki/File:Electron_transport_chain.svg.
7. Langsjoen
PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and
the associated depletion of coenzyme Q10. A review of animal and human
publications. Biofactors. 2003;18(1–4):101–111. [PubMed]
8. Trifunovic A. Mitochondrial DNA and ageing. Biochim Biophys Acta. 2006;1757(5–6):611–617. [PubMed]
9. Kalghatgi
S, Spina CS, Costello JC, et al. Bactericidal antibiotics induce
mitochondrial dysfunction and oxidative damage in Mammalian cells. Sci Transl Med. 2013;5(192):192ra85. [PMC free article] [PubMed]
10. Ray
KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in
high-risk primary prevention: a meta-analysis of 11 randomized
controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024–1031. [PubMed]
11. Manzo-Avalos S, Saavedra-Molina A. Cellular and mitochondrial effects of alcohol consumption. Int J Environ Res Public Health. 2010;7(12):4281–4304. [PMC free article] [PubMed]
12. Mitochondrial
Medicine Society’s Committee on Diagnosis. Haas RH, Parikh S, et al.
The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab. 2008;94(1):16–37. [PMC free article] [PubMed]
13. Valavanidis
A, Vlachogianni T, Fiotakis C. 8-hydroxy-2′-deoxyguanosine (8-OHdG): a
critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009;27(2):120–139. [PubMed]
14. Scheibye-Knudsen
M, Scheibye-Alsing K, Canugovi C, et al. A novel diagnostic tool
reveals mitochondrial pathology in human diseases and aging. Aging. 2013;5(3):192–208. [PMC free article] [PubMed]
15. Kelly
NA, Ford MP, Standaert DG, et al. Novel, high-intensity exercise
prescription improves muscle mass, mitochondrial function, and physical
capacity in individuals with Parkinson’s disease. J Appl Physiol. 1985 2014 Jan; [Epub ahead of print] [PMC free article] [PubMed]
16. Lenaz G, D’Aurelio M, Merlo Pich M, et al. Mitochondrial bioenergetics in aging. Biochim Biophys Acta. 2000;1459:397–404. [PubMed]
17. Hargreaves IP. Coenzyme Q10 as a therapy for mitochondrial disease. Int J Biochem Cell Biol. 2014 Feb 2; doi: 10.1016/j.biocel.201401.020. [PubMed] [Cross Ref]
18. Shenk
JC, Liu J, Fischbach K, et al. The effect of acetyl-L-carnitine and
R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human
Alzheimer’s disease. J Neurol Sci. 2009;283(1–2):199–206. [PMC free article] [PubMed]
19. McMackin
CJ, Widlansky ME, Hamburg NM, et al. Effect of combined treatment with
alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood
pressure in patients with coronary artery disease. J Clin Hypertens (Greenwich) 2007;9(4):249–255. [PMC free article] [PubMed]
20. Lagouge
M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves
mitochondrial function and protects against metabolic disease by
activating SIRT1 and PGC-1α Cell. 2006;127(6):1109–1122. [PubMed]
21. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J Biol Chem. 2005;280(45):37377–37382. [PubMed]
22. Timmers
S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30
days of resveratrol supplementation on energy metabolism and metabolic
profile in obese humans. Cell Metab. 2011;14(5):612–622. [PMC free article] [PubMed]
23. Navarro A, Boveris A. Brain mitochondrial dysfunction in aging, neurodegeneration, and Parkinson’s disease. Front Aging Neurosci. 2010;2(pii):34. doi: 10.3389/fnagi.2010.00034. [PMC free article] [PubMed] [Cross Ref]